公开(公告)号：US20230132397A9

公开(公告)日：2023-04-27

申请号：US17263515

申请日：2019-07-26

申请人： Children's Medical Center Corporation ,  Dana-Farber Cancer Institute, Inc.

发明人： David J. Dowling ,  Ofer Levy ,  Francesco Borriello ,  David A. Scott ,  Spencer E. Brightman

IPC分类号： A61K39/39 ,  A61K45/06 ,  A61K31/739 ,  A61K31/4535 ,  A61K31/381 ,  A61K31/496 ,  A61K31/438 ,  A61K31/4025

摘要： Provided herein are Toll-like receptor 2 (TLR2) agonists for use in enhancing human immune response and/or as adjuvants in vaccines. The TLR2 agonists include thiophenes, imidazoles, or phenyl-containing compounds, which may be compounds of Formulae (I), (II), (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease, (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

公开(公告)号：US20230082623A1

公开(公告)日：2023-03-16

申请号：US17457727

申请日：2021-12-06

申请人： Vigil Neuroscience, Inc.

发明人： Spyridon PAPAPETROPOULOS ,  Richard FISHER ,  Matthew BRENNAN

IPC分类号： C07K16/28 ,  A61K31/739 ,  A61K38/17 ,  A61P25/00

摘要： The present invention provides a method of treating a disease or disorder caused by and/or associated with ABCD1 dysfunction in a human patient, the method comprising administering to the patient in need thereof an effective amount of a compound that increases the activity of triggering receptor expressed on myeloid cells 2 (TREM2). In some embodiments, compound that increases the activity of TREM2 is an agonist of TREM2. In some embodiments, the agonist of TREM2 is a small molecule agonist of TREM2 or an antibody agonist of TREM2.

公开(公告)号：US20230042693A1

公开(公告)日：2023-02-09

申请号：US17785312

申请日：2020-12-22

申请人： BIOPOLIS, S.L.

发明人： Patricia MARTORELL GUEROLA ,  Ferran BALAGUER VIDAL ,  Maria ENRIQUE LOPEZ ,  Marta TORTAJADA SERRA ,  Daniel RAMON VIDAL ,  Marta BARRENA CASTILLO ,  Blake HAMMANN ,  Beatriz ALVAREZPEREZ ,  Empar CHENOLL CUADROS

IPC分类号： C08B37/00 ,  A61K31/739 ,  A61P3/04 ,  A23L33/135 ,  A23L33/00 ,  A23K10/16

摘要： The present invention relates to a lipoteichoic acid isolated from Bifidobacteria cultured in excess of glucose which has fat reduction activity, thus being useful for exploitation in the following application areas: food and beverages, animal feed, including pet food, nutritional supplements, infant nutrition, cosmetics (including nutricosmetics), medical foods and pharmaceutical and veterinary applications, among others.

公开(公告)号：US11369473B2

公开(公告)日：2022-06-28

申请号：US16377314

申请日：2019-04-08

申请人： Loubert S. Suddaby

发明人： Loubert S. Suddaby

IPC分类号： A61F2/28 ,  A61K38/20 ,  A61L27/12 ,  A61L27/54 ,  A61L27/56 ,  A61K31/739 ,  A61K39/108 ,  A61K39/085 ,  A61L27/08 ,  A61L27/02 ,  A61L27/18 ,  A61L27/06 ,  A61L27/36 ,  A61K38/21 ,  A61F2/30

摘要： An extended release immunomodulatory implant operatively arranged to facilitate bone morphogenesis, including an inner portion including one or more interleukins, and an outer portion including an immunomodulatory stimulant such as an antigen.

公开(公告)号：US11266602B2

公开(公告)日：2022-03-08

申请号：US16098619

申请日：2017-05-15

申请人： Infectious Disease Research Institute ,  University of Virginia Patent Foundation

发明人： Christopher B. Fox ,  Susan S. Lin ,  Darrick Carter ,  Neal Van Hoeven ,  Mayuresh M. Abhyankar ,  William A. Petri

IPC分类号： A61K9/127 ,  A61K31/739 ,  A61K39/39 ,  A61K39/00

摘要： Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.

公开(公告)号：US20220031766A1

公开(公告)日：2022-02-03

申请号：US17345044

申请日：2021-06-11

申请人： 4D Pharma Research Limited

发明人： Imke Elisabeth MULDER ,  Amy Beth HOLT ,  Domenico PANZICA ,  Seanin Marie MCCLUSKEY

IPC分类号： A61K35/74 ,  A61K35/744 ,  C12N1/20 ,  A23L33/135 ,  A23C9/158 ,  A61K9/19 ,  A61K31/739 ,  A61K39/09 ,  A61K45/06

摘要： The invention provides compositions comprising bacterial strains for treating and preventing cancer.

公开(公告)号：US20210379129A1

公开(公告)日：2021-12-09

申请号：US17283283

申请日：2019-10-07

申请人： BIOCOMO INCORPORATION ,  MIE UNIVERSITY

发明人： Masayuki FUKUMURA ,  Junpei OHTSUKA ,  Tetsuya NOSAKA

IPC分类号： A61K35/76 ,  A61K31/739 ,  A61K35/741 ,  C07K16/28 ,  A61P35/00

摘要： An anticancer agent contains a virus presenting a desired protein or peptide on a virus particle envelope, as an active ingredient.

公开(公告)号：US20210268070A1

公开(公告)日：2021-09-02

申请号：US17258248

申请日：2019-07-10

申请人： Rush University Medical Center

发明人： Sasha Hadi SHAFIKHANI

IPC分类号： A61K38/19 ,  A61K31/739 ,  A61K38/06 ,  A61K45/06 ,  A61P17/02

摘要： Methods and compositions are provided for treating an infection and promoting wound healing. The methods include administering an immunomodulator. In some aspects, the immunomodulator may be combined with an antibiotic.

公开(公告)号：US10918709B2

公开(公告)日：2021-02-16

申请号：US16345699

申请日：2017-10-30

申请人： EYEGENE INC.

发明人： Yang Je Cho ,  Kwangsung Kim ,  Na Gyong Lee ,  Shin Ae Park

IPC分类号： A61K39/12 ,  A61P31/12 ,  A61K39/39 ,  C08B37/00 ,  A61K31/739 ,  A61K39/002 ,  A61K39/00 ,  A61K39/295

摘要： The present invention relates to an immune modulator having a novel structure, and an immunologic adjuvant composition containing the same and, more specifically, to an modulator, which is a lipopolysaccharide (LPS) analog having reduced toxicity, and a use thereof. The immune modulator of the present invention exhibits immune enhancement effects by having excellent innate immunity and ability to induce an adaptive immune response to a specific pathogen, and is very safe by having low toxicity. In addition, a vaccine containing the immune modulator of the present invention contains both an immune modulator and an alum, thereby improving immune enhancement effects compared with when using only the immune modulator.

公开(公告)号：US10857177B2

公开(公告)日：2020-12-08

申请号：US15753129

申请日：2016-08-19

申请人： President and Fellows of Harvard College

发明人： Sungwhan Oh ,  Deniz Erturk-Hasdemir ,  Dennis L. Kasper

IPC分类号： A61K45/00 ,  A61K31/739 ,  C08B37/00 ,  A61K47/54 ,  A61P37/06 ,  A61P31/04 ,  A61P29/00 ,  A61K9/107 ,  A61K9/127

摘要： The invention provides various isolated and synthetic forms of lipidated PSA as well as isolated or synthetic forms of the glycolipid component of lipidated PSA, and compositions thereof, methods of making including methods of isolating such forms, and methods of use thereof.